[2(1)[NHS England] must determine the elements of pharmaceutical remuneration in respect of which apportionments are to be made in relation to a financial year in accordance with this paragraph.E+W
(2)In this Schedule, those elements of pharmaceutical remuneration are referred to as “designated elements”.
(3)[NHS England] must notify each [integrated care board] of a determination under sub-paragraph (1).
(4)[NHS England] must apportion the sums paid by it in respect of each designated element during the financial year among all [integrated care boards], in such manner as [NHS England] thinks appropriate.
(5)In apportioning sums under sub-paragraph (4), [NHS England] may, in particular, take into account the financial consequences of orders for the provision of drugs that are attributable to the members of each [integrated care board].
(6)Where an amount of pharmaceutical remuneration is apportioned to [an integrated care board], [NHS England]—
(a)may deduct that amount from the sums that it would otherwise pay to [the board] under section 223G(1), and
(b)if it does so, must notify [the board] accordingly.
(7)The Secretary of State may direct [NHS England] that an element of pharmaceutical remuneration specified in the direction is not to be included in a determination under sub-paragraph (1).
(8)In determining the amount to be allotted to [an integrated care board] for the purposes of section 223G, [NHS England] must take into account the effect of this Schedule.
[(9)For the purposes of sections 223GC and 223M(1)(b) and paragraph 22 of Schedule 1B, any amount of which an integrated care board is notified under sub-paragraph (6) is to be treated as expenditure of the group which is attributable to the performance by it of its functions in the year in question.]]